Status:
COMPLETED
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Lead Sponsor:
Stanford University
Collaborating Sponsors:
United States Department of Defense
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 18 years of age and older
- Histologically documented adenocarcinoma of prostate
- Currently receiving LHRH agonists with castrate levels of testosterone or who have had an orchiectomy
- Must have had a rise in PSA despite anti androgen withdrawal
- Exhibit 2 consecutive rise in PSA after the last hormonal manipulation
- Minimum PSA of greater than 5 KPS greater than 80%
- Normal cortisol level at entry
- Life expectancy greater than 6 months
- Provide written consent pursuant to regulatory requirements prior to initiation of study procedure
- Exclusion criteria:
- Younger than 18 years
- Patients without prostate cancer
Exclusion
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00186108
Start Date
October 1 2002
End Date
September 1 2005
Last Update
July 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Cancer Center
Stanford, California, United States, 94305